The Solid Dosage Formulations business is supported up by our in-house R&D facility for formulation development and regulatory filings.
The business operates from world class facilities, equipped for carrying out bio-equivalence studies for the generics R&D program and cost effective manufacturing, and at the same time deriving benefits from backward integration from our APIs business. Our primary focus is on developing, manufacturing and sale of proprietary Solid Dosage Formulations including value-added formulations for Cardiovascular System (CVS), Central Nervous System (CNS) and Anti-allergy categories.
We have commercialised products across geographies including the United States and Europe. We are standing firm as one of the largest exporters of Oral Solid Formulations to Japan. This business helps in developing first-to-market generic drugs, innovative drugs, over-theounter drugs and line extensions. Our range of products also includes value-added formulations and special formulations such as taste masking, flash tablets, oral dispersible forms, chewable tablets and modified release forms.
We have two manufacturing facilities catering to our formulations business, one at Roorkee, Uttarakhand, India approved by UKMHRA, US FDA, Japanese PMDA, Brazil ANVISA and PICS another at Salisbury, Maryland, USA a US FDA approved facility.
Sustaining our leadership in the US for Methylprednisolone, Terazosin and Lamotrigine is a constant endeavour. We are one of the leaders in Meclizine, Cyclobenzaprine, prochlorperazine, Donepezil and HCTZ Caps. Our key strengths in Europe include regulatory affairs services, formulation development, and licensing of marketing authorisations in addition to supplies of Solid Dosage Formulations to makers of generic products as well.
We are aiming to expand the sales reach in the United States, directly to the government agencies and distributors through our Jubilant Cadista business. We also plan to continue strategic licenses for our products to third parties in various European countries with regulatory encouragements from our subsidiaries.
Backed by strong research team, the areas of focus for R&D is IR-Dosage Forms, Novel Drug Delivery Systems (NDDS), Analytical Development, Regulatory Affairs, Medical Affairs, Patent Cell and Packaging Development. Offering product development and research in Oral Liquids, Tablets, Hard Gelatin Capsules, Oral Controlled Release and Value Added Generics – Oral.